0      0

JL1111ES - JL1111ES: EMERALD trial analysis of patient-reported outcomes (PROs) in patients with ER+/HER2− advanced or metastatic breast cancer (mBC) comparing oral elacestrant vs standard of care (SoC) endocrine therapy

‐ Oct 24, 2023 12:00am

Javier Cortes, MD, PhD;1 Francois-Clement Bidard, MD, PhD;2 Aditya Bardia, MD, MPH;3 Virginia Kaklamani, MD;4 Ionna Vlachaki;5 Giulia Tonini;5 Nassir Habboubi, MD;6 Phillipe Aftimos, MD;7



You must be logged in and own this session in order to post comments.